HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.
Journal
Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
06
03
2019
revised:
20
01
2020
accepted:
23
07
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
15
12
2021
Statut:
ppublish
Résumé
Herpes simplex virus (HSV) glycoprotein D (gD) not only is required for virus entry and cell-to-cell spread but also binds the host immunomodulatory molecule, HVEM, blocking interactions with its ligands. Natural infection primarily elicits neutralizing antibodies targeting gD, but subunit protein vaccines designed to induce this response have failed clinically. In contrast, preclinical studies demonstrate that an HSV-2 single-cycle strain deleted in gD, ΔgD-2, induces primarily non-neutralizing antibodies that activate Fcγ receptors (FcγRs) to mediate antibody-dependent cellular cytotoxicity (ADCC). These studies were designed to test the hypothesis that gD interferes with ADCC through engagement of HVEM. Immunization of
Identifiants
pubmed: 32817296
pii: 5/50/eaax2454
doi: 10.1126/sciimmunol.aax2454
pmc: PMC7673108
mid: NIHMS1641481
pii:
doi:
Substances chimiques
Receptors, Tumor Necrosis Factor, Member 14
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI117321
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI067890
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM104547
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134824
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA177322
Pays : United States
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Immunol Rev. 2009 May;229(1):244-58
pubmed: 19426226
Cell Microbiol. 2004 May;6(5):401-10
pubmed: 15056211
Nat Rev Immunol. 2006 Sep;6(9):671-81
pubmed: 16932752
Structure. 2013 Aug 6;21(8):1396-405
pubmed: 23850455
J Infect Dis. 2020 Feb 18;221(5):729-738
pubmed: 31599942
J Leukoc Biol. 2010 Feb;87(2):223-35
pubmed: 20007250
Nat Immunol. 2008 Feb;9(2):176-85
pubmed: 18193050
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6994-8
pubmed: 10359827
J Exp Med. 2018 Jun 4;215(6):1589-1608
pubmed: 29794117
Eur J Immunol. 2009 Dec;39(12):3343-56
pubmed: 19795417
Sci Adv. 2016 Apr 08;2(4):e1500637
pubmed: 27152329
J Infect Dis. 2003 Feb 15;187(4):542-9
pubmed: 12599070
Cell Host Microbe. 2018 Aug 8;24(2):249-260.e4
pubmed: 30092201
NPJ Vaccines. 2020 May 7;5:35
pubmed: 32411398
Immunity. 2019 Aug 20;51(2):310-323.e7
pubmed: 31204070
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5545-50
pubmed: 11960012
PLoS One. 2015 Jan 21;10(1):e114989
pubmed: 25608026
J Exp Med. 2002 Jun 17;195(12):1613-24
pubmed: 12070288
Ann Intern Med. 1983 Jun;98(6):958-72
pubmed: 6344712
J Virol. 1988 May;62(5):1486-94
pubmed: 2833603
J Virol. 2015 Sep;89(18):9213-31
pubmed: 26109729
J Clin Invest. 2005 Mar;115(3):711-7
pubmed: 15696194
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6244-9
pubmed: 19332782
J Virol. 2006 Apr;80(8):3985-93
pubmed: 16571815
JCI Insight. 2016 Aug 4;1(12):
pubmed: 27536733
Rev Infect Dis. 1991 Jan-Feb;13(1):108-14
pubmed: 2017608
Sex Transm Dis. 2003 Oct;30(10):797-800
pubmed: 14520181
EMBO J. 2006 Sep 20;25(18):4390-9
pubmed: 16932746
Cell Host Microbe. 2007 Jul 12;2(1):19-28
pubmed: 18005714
PLoS One. 2011 Mar 11;6(3):e17748
pubmed: 21412438
J Virol. 2010 Nov;84(22):11646-60
pubmed: 20826693
Nat Immunol. 2003 Jul;4(7):670-9
pubmed: 12796776
Vaccines (Basel). 2020 Jun 05;8(2):
pubmed: 32516944
J Virol. 2010 Jan;84(1):163-75
pubmed: 19846533
Cold Spring Harb Perspect Biol. 2014 Dec 18;7(4):a016279
pubmed: 25524549
J Virol. 2011 Feb;85(4):1896-9
pubmed: 21123389
J Infect Dis. 2011 May 15;203(10):1434-41
pubmed: 21498376
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19396-401
pubmed: 20974962
J Virol. 2013 Feb;87(3):1443-53
pubmed: 23152529
Infect Immun. 1984 Feb;43(2):761-4
pubmed: 6319291
J Virol. 2000 Sep;74(17):7963-71
pubmed: 10933704
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Elife. 2015 Mar 10;4:
pubmed: 25756612
J Virol. 2014 Nov;88(21):12612-22
pubmed: 25142599
Immunity. 2016 May 17;44(5):1005-19
pubmed: 27192566
N Engl J Med. 2012 Jan 5;366(1):34-43
pubmed: 22216840
JAMA. 1999 Jul 28;282(4):331-40
pubmed: 10432030
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13218-23
pubmed: 16131544
Methods Mol Biol. 2012;844:177-81
pubmed: 22262442
Immunogenetics. 1989;29(2):92-7
pubmed: 2563358
Cell. 1996 Nov 1;87(3):427-36
pubmed: 8898196
J Virol. 2002 Jan;76(1):1-8
pubmed: 11739666
Immunity. 2005 Jul;23(1):41-51
pubmed: 16039578
J Immunol. 2010 Jul 1;185(1):532-41
pubmed: 20505139
PLoS Pathog. 2011 Oct;7(10):e1002279
pubmed: 21998581
J Infect Dis. 2018 Feb 14;217(5):754-758
pubmed: 29216362
J Virol. 1998 Nov;72(11):8933-42
pubmed: 9765438
J Immunol. 2009 Dec 1;183(11):7286-96
pubmed: 19915044
Science. 1987 May 22;236(4804):944-7
pubmed: 3107127
J Virol. 2013 Jan;87(1):474-81
pubmed: 23097453
mBio. 2015 Jun 30;6(4):e00801
pubmed: 26126854
N Engl J Med. 2002 Nov 21;347(21):1652-61
pubmed: 12444179
Nature. 2009 Jul 9;460(7252):264-8
pubmed: 19525933
J Infect Dis. 1989 Nov;160(5):770-6
pubmed: 2553825
J Virol. 2003 Sep;77(17):9695-9
pubmed: 12915581
Gut Microbes. 2013 Mar-Apr;4(2):146-51
pubmed: 23333859
Immunity. 1998 Jan;8(1):21-30
pubmed: 9462508
J Immunol. 2007 Nov 15;179(10):6901-9
pubmed: 17982081
Nat Immunol. 2005 Jan;6(1):90-8
pubmed: 15568026
Annu Rev Immunol. 2010;28:389-411
pubmed: 20307212
PLoS One. 2012;7(10):e46714
pubmed: 23071620
NPJ Vaccines. 2018 Sep 20;3:38
pubmed: 30275984
Immunol Rev. 2011 Nov;244(1):169-87
pubmed: 22017438
Curr Opin Virol. 2014 Jun;6:6-12
pubmed: 24631871
Clin Vaccine Immunol. 2006 Sep;13(9):981-90
pubmed: 16960108